Key result
Sotagliflozin treatment improved cardiac function and reduced infarct size, cardiac hypertrophy, apoptosis, and inflammation compared with vehicle in post-myocardial infarction rats.
Why the study?
While SGLT2 inhibitors improve cardiac function and reduce infarct size in animal models of MI, whether dual SGLT1/2 inhibition with sotagliflozin provides beneficial cardioprotective effects remained unknown.
Does sotagliflozin improve cardiac function and attenuate remodeling in a rat model of myocardial infarction?
RCT
randomly assigned
Does sotagliflozin improve cardiac function and attenuate remodeling in a rat model of myocardial infarction?
Sotagliflozin, a dual SGLT1/2 inhibitor, attenuates cardiac dysfunction, remodeling, and inflammation in a rat model of myocardial infarction.
Objective: Sotagliflozin is a dual sodium-glucose co-transporter-1 and 2 (SGLT1/2) inhibitor with selectivity towards SGLT2. Previous studies showed that SGLT2 inhibitors can improve cardiac function and reduce myocardial infarction size in animal models of myocardial infarction (MI). However, it remains unknown whether the dual inhibition of SGLT1/2 by sotagliflozin has beneficial effects in this context. In this study, we investigated the potential cardioprotective effects of sotagliflozin in an animal model of MI. Methods: Sprague Dawley (SD) rats underwent left anterior descending coronary artery ligation or sham ligation then were randomly assigned to receive either sotagliflozin (10 mg/kg) or vehicle via intraperitoneal injection. Fourteen days post-MI, we assessed cardiac function using echocardiography and evaluated histological and molecular markers of cardiac remodeling and inflammation in the left ventricle. Results: Our findings indicate that sotagliflozin treatment resulted in improved cardiac function and reduced infarct size compared with the vehicle-treated group. Additionally, sotagliflozin improved cardiac remodeling as shown by the decreased cardiac hypertrophy and cardiac apoptosis in the post-MI heart. Mechanistically, an apparent reduction in the cardiac inflammatory response in sotagliflozin-treated hearts was observed in the post-MI rats. Conclusion: Overall, our results suggest that sotagliflozin may have cardioprotective effects against myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2023) conducted an RCT in myocardial infarction. Sotagliflozin vs. Vehicle was evaluated on Cardiac function and infarct size. Sotagliflozin treatment improved cardiac function and reduced infarct size, cardiac hypertrophy, apoptosis, and inflammation compared with vehicle in post-myocardial infarction rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: